FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078839103> ?p ?o ?g. }

• W2078839103 endingPage "30" @default.
• W2078839103 startingPage "23" @default.
• W2078839103 abstract "The secretory capacity, in vivo, of clinically non-functioning pituitary adenomas may possibly predict tumour volume reduction during intensive medical therapy. Ten patients (mean (range) 53 years (26-73)) with clinically non-functioning macroadenomas, > or = 10 mm were studied. The secretory capacity of the adenomas was examined using basal, NaCl and TRH-stimulated LH, FSH and alpha-subunit levels. The effect on tumour volume of 6 months' therapy with the combination of a somatostatin analogue, octreotide 200 microg x 3/day and a dopamine-D2-agonist, cabergoline 0.5 mg x 1/day was studied. The basal LH, FSH and alpha-subunit levels were determined before and during 6 months' therapy with octreotide and cabergoline, and MR scans were used to evaluate tumour volume before and during this period of therapy. Octopus-perimetry was used to examine the visual fields. A reduction in tumour volume (mean +/- SEM (range); 30% +/- 4% (18-46%)) during 6 months of combination therapy with octreotide and cabergoline was recorded only in patients with in vivo secretory potential. Tumour volume was not reduced in four patients: in three of these patients it remained unchanged while in one patient it was observed to have increased (by 14%). Of the six patients with pretherapy secretory capacity, one displayed a very high basal level of alpha-subunit (74 microg/l) despite unmeasurable levels of LH and TSH, and an FSH-level of 1 IU/l. The other five patients presented paradoxical LH, FSH and/or alpha-subunit responses to TRH. A reduction in basal levels of LH, FSH and/or alpha-subunit was observed in all six patients, and the maximum reduction of at least one of the hormonal levels was 66% +/- 7% (50-98%). The basal levels of LH, FSH and alpha-subunit in the 10 patients were (mean +/- SEM (range)), 3.0 IU/l +/- 1.0 (0.0-7.4), 12.7 IU/l +/- 5.0 (0.0-39.0) and 9.0 IU/l +/- 7.0 (0.2-74.0). During six months of therapy with octreotide and cabergoline, the basal levels of LH, FSH and alpha-subunit were reduced by > or = 50% in seven patients - including the six patients with in vivo secretion prior to therapy. No new visual field defects were detected during therapy and no deterioration of existing visual field defects was recorded. The medical therapy was well tolerated. The in vivo basal and TRH-stimulated secretory capacity of LH, FSH and alpha-subunit predicted tumour reduction following intensive medical therapy in all of our patients with non-functioning pituitary adenomas." @default.
• W2078839103 created "2016-06-24" @default.
• W2078839103 creator A5030052985 @default.
• W2078839103 creator A5036975649 @default.
• W2078839103 creator A5046096833 @default.
• W2078839103 creator A5075840216 @default.
• W2078839103 creator A5077029779 @default.
• W2078839103 creator A5080440172 @default.
• W2078839103 creator A5081845117 @default.
• W2078839103 date "2001-01-01" @default.
• W2078839103 modified "2023-10-16" @default.
• W2078839103 title "<i>In vivo</i> secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas" @default.
• W2078839103 cites W1967676176 @default.
• W2078839103 cites W1974019100 @default.
• W2078839103 cites W1979868498 @default.
• W2078839103 cites W1983498173 @default.
• W2078839103 cites W1985040872 @default.
• W2078839103 cites W1996331131 @default.
• W2078839103 cites W1999329523 @default.
• W2078839103 cites W2003589817 @default.
• W2078839103 cites W2024881534 @default.
• W2078839103 cites W2025301270 @default.
• W2078839103 cites W2027616003 @default.
• W2078839103 cites W2029081741 @default.
• W2078839103 cites W2031506020 @default.
• W2078839103 cites W2031565988 @default.
• W2078839103 cites W2035389128 @default.
• W2078839103 cites W2042944352 @default.
• W2078839103 cites W2047638867 @default.
• W2078839103 cites W2049486103 @default.
• W2078839103 cites W2091336801 @default.
• W2078839103 cites W2135488489 @default.
• W2078839103 cites W2136943315 @default.
• W2078839103 cites W4234912535 @default.
• W2078839103 cites W4239277776 @default.
• W2078839103 cites W4243520555 @default.
• W2078839103 doi "https://doi.org/10.1046/j.1365-2265.2001.01172.x" @default.
• W2078839103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11167922" @default.
• W2078839103 hasPublicationYear "2001" @default.
• W2078839103 type Work @default.
• W2078839103 sameAs 2078839103 @default.
• W2078839103 citedByCount "59" @default.
• W2078839103 countsByYear W20788391032012 @default.
• W2078839103 countsByYear W20788391032013 @default.
• W2078839103 countsByYear W20788391032014 @default.
• W2078839103 countsByYear W20788391032015 @default.
• W2078839103 countsByYear W20788391032016 @default.
• W2078839103 countsByYear W20788391032017 @default.
• W2078839103 countsByYear W20788391032018 @default.
• W2078839103 countsByYear W20788391032019 @default.
• W2078839103 countsByYear W20788391032020 @default.
• W2078839103 countsByYear W20788391032021 @default.
• W2078839103 crossrefType "journal-article" @default.
• W2078839103 hasAuthorship W2078839103A5030052985 @default.
• W2078839103 hasAuthorship W2078839103A5036975649 @default.
• W2078839103 hasAuthorship W2078839103A5046096833 @default.
• W2078839103 hasAuthorship W2078839103A5075840216 @default.
• W2078839103 hasAuthorship W2078839103A5077029779 @default.
• W2078839103 hasAuthorship W2078839103A5080440172 @default.
• W2078839103 hasAuthorship W2078839103A5081845117 @default.
• W2078839103 hasConcept C126322002 @default.
• W2078839103 hasConcept C134018914 @default.
• W2078839103 hasConcept C150903083 @default.
• W2078839103 hasConcept C207001950 @default.
• W2078839103 hasConcept C2776297358 @default.
• W2078839103 hasConcept C2778024521 @default.
• W2078839103 hasConcept C2779064019 @default.
• W2078839103 hasConcept C2779306644 @default.
• W2078839103 hasConcept C2779832395 @default.
• W2078839103 hasConcept C2781025020 @default.
• W2078839103 hasConcept C71315377 @default.
• W2078839103 hasConcept C71924100 @default.
• W2078839103 hasConcept C86803240 @default.
• W2078839103 hasConceptScore W2078839103C126322002 @default.
• W2078839103 hasConceptScore W2078839103C134018914 @default.
• W2078839103 hasConceptScore W2078839103C150903083 @default.
• W2078839103 hasConceptScore W2078839103C207001950 @default.
• W2078839103 hasConceptScore W2078839103C2776297358 @default.
• W2078839103 hasConceptScore W2078839103C2778024521 @default.
• W2078839103 hasConceptScore W2078839103C2779064019 @default.
• W2078839103 hasConceptScore W2078839103C2779306644 @default.
• W2078839103 hasConceptScore W2078839103C2779832395 @default.
• W2078839103 hasConceptScore W2078839103C2781025020 @default.
• W2078839103 hasConceptScore W2078839103C71315377 @default.
• W2078839103 hasConceptScore W2078839103C71924100 @default.
• W2078839103 hasConceptScore W2078839103C86803240 @default.
• W2078839103 hasIssue "1" @default.
• W2078839103 hasLocation W20788391031 @default.
• W2078839103 hasLocation W20788391032 @default.
• W2078839103 hasOpenAccess W2078839103 @default.
• W2078839103 hasPrimaryLocation W20788391031 @default.
• W2078839103 hasRelatedWork W1992516356 @default.
• W2078839103 hasRelatedWork W1993017717 @default.
• W2078839103 hasRelatedWork W2013777072 @default.
• W2078839103 hasRelatedWork W2046917110 @default.
• W2078839103 hasRelatedWork W2050730962 @default.
• W2078839103 hasRelatedWork W2059331087 @default.
• W2078839103 hasRelatedWork W2088717006 @default.

• next